IMGN3322

IMGN3322 is an orally available, highly selective small molecule inhibitor of Tyrosine Kinase 2 (TYK2) currently in Phase 2 clinical development for the treatment of moderate-to-severe atopic dermatitis. Developed by Inmagene Biopharmaceutics (which announced a merger with Ikena Oncology in late 2024), IMGN3322 targets the TYK2 enzyme to block the signaling pathways of key pro-inflammatory cytokines, including interleukin-23 (IL-23), interleukin-12 (IL-12), and Type I interferons (IFN). By specifically targeting the pseudokinase domain of TYK2, such inhibitors aim to achieve high selectivity over other Janus kinase (JAK) family members (JAK1, JAK2, and JAK3), potentially reducing the risk of off-target side effects such as cytopenia or lipid elevations.